Journal profile · Pharmacology, Toxicology and Pharmaceutics-Pharmacology
Current Pharmacology Reports
ISSN 2198-641X · Springer Nature · 6 issues per year
Current Pharmacology Reports: CAS Zone 4 · Medicine (2026 Xinrui edition); impact factor 1.8 (journal website); hybrid open access; APC about USD 4,790; median 164 days to acceptance (46 articles, last 24 months); 50 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Current Pharmacology Reports is published by Springer Nature and is classed under Medicine in the CAS Journal Ranking. By OpenAlex counts of its recent articles, its largest topics are Epigenetics and DNA Methylation, Genomics, phytochemicals, and oxidative stress and Phytochemicals and Antioxidant Activities, together about 20.6% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Current Pharmacology Reports will: publish cutting-edge reviews on subjects pertinent to all aspects of pharmacology, including drug discovery and development. provide incisive, insightful, and balanced contributions from international leading experts. interest a wide readership of basic scientists and translational investigators in academia and in industry. The Current Pharmacology Reports journal accomplishes its goal by appointing international authorities to serve as Section Editors in key subject areas, such as: epigenetics and epigenomics, chemoinformatics and rational drug design and target discovery, drug delivery and biomaterial, pharmacogenomics and molecular targets and biomarkers, chemical/drug/molecular toxicology, absorption, distribution, metabolism and elimination (ADME), pharmacokinetics (PK) and pharmacodynamics (PD), Modeling & Simulation (M&S) and pharmacometrics, and other related topics in pharmacology including neurology/central nervous system (CNS), cardiovascular, metabolic diseases, cancer, among others. Section Editors for Current Pharmacology Reports select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided. This journal publishes on a bi-monthly schedule. Single-blind peer review: The journal follows a single-blind review procedure, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. Single-blind peer review is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript. Please submit here: https://submission.nature.com/new-submission/40495/3
From the journal's Aims & Scope
Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-Pharmacology
Editor-in-chief Luigi BrunettiPublisher website
Editorial board by country: 3 in mainland China (about 6%); most named United States 24, Mainland China 3, South Korea 3, India 3, Taiwan, China 2 (48 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology7%
- Genomics, phytochemicals, and oxidative stressBiochemistry, Genetics and Molecular Biology7%
- Phytochemicals and Antioxidant ActivitiesMedicine6.7%
- Computational Drug Discovery MethodsComputer Science6.7%
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics5.7%
- Natural Antidiabetic Agents StudiesMedicine4.8%
- SARS-CoV-2 and COVID-19 ResearchMedicine4.2%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbaseCASPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 1.8Publisher website ·
- CiteScore 2026-06
- 4.6LetPub ·
- SJR 2026-06
- 0.5LetPub ·
- SNIP 2026-06
- 0.55LetPub ·
- h-index
- 49OpenAlex ·
- i10-index
- 209OpenAlex ·
- 2-year mean citedness
- 3.07OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 10.08%LetPub ·
Volume
- Articles per year
- 57LetPub ·
- Downloads per year (publisher) 2025
- 163,000Publisher website ·
Articles by year OpenAlex count · 472 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 40 | 6 | 20 |
| 2025 | 50 | 12 | 196 |
| 2024 | 37 | 3 | 174 |
| 2023 | 41 | 6 | 255 |
| 2022 | 38 | 11 | 659 |
| 2021 | 22 | 8 | 468 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
164 daysMedian, submission to acceptance · P25–P75 90 days – 227 days
- Acceptance to online
- median 15 days (88 articles)
- Submission to online
- median 177 days
- Sample
- 46 articles with submission and acceptance dates (105 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to first decision
- 14 daysPublisher website ·
- Peer review
- Single anonymous peer review, Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,790 / EUR 3,790 / GBP 2,990 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
Article types accepted1
- editorialSingle-blind peer review This journal follows a single-blind reviewing procedure. This journal also publishes special/guest-edited issues. The peer review proce…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Trial registration / reporting guidelines
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
Source ↗Publisher website ·- Data availability Data availability statements
All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here. If it is not possible to share research data publicly, for instance when individual privacy could be com…
Source ↗Publisher website ·- Publication ethics Compliance with Ethical Standards
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
Source ↗Publisher website ·- License & copyright Copyright
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Current Pharmacology Reports, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Peer review Single-blind peer review
This journal follows a single-blind reviewing procedure. This journal also publishes special/guest-edited issues. The peer review process for these articles is the same as the peer review process of the journal in general. Additionally, if a guest editor authors an article in their issue/collection, they will not handle the peer review process.
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Frequency
- 6 issues per year
- ISSN
- 2198-641X
- Official links
- Journal homepage ↗OpenAlex
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Current Pharmacology Reports
What CAS zone is Current Pharmacology Reports in?
In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Current Pharmacology Reports?
The journal's website gives an impact factor of 1.8 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 4.6, h-index 49.
How long does peer review take at Current Pharmacology Reports?
Based on the dates recorded on 46 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 164 days (interquartile range 90–227 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Current Pharmacology Reports?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Reference style: Numbered, in order of citation; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Current Pharmacology Reports based?
Of the 48 board members whose country the journal's board page names, 3 (about 6%) are in mainland China; the countries named most often are United States (24), Mainland China (3) and South Korea (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Current Pharmacology Reports?
According to LetPub and DOAJ records, Current Pharmacology Reports is indexed in ESCI and Scopus. The journal's website also lists Embase and CAS; that list has not been checked against each database.
Is Current Pharmacology Reports open access, and what is the APC?
Current Pharmacology Reports is a hybrid journal. For open-access publication: APC about USD 4,790.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .